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Diabetes control in older people
Treat the patient not the HbA1c
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Medical providers must prepare for two important demographic
changes—the increase in life expectancy and the fact that we
are getting fatter. As a consequence, the prevalence of diabetes
is rising across the age spectrum, including among older people.
People over the age of 65 years with diabetes experience higher
rates of microvascular and macrovascular complications, which
leads to increased hospital admissions, healthcare expenditure,
and requirements for social care. Treating older people with
diabetes is challenging, not least because the risks of
hypoglycaemia and associated complications from overly
aggressive treatment are also increased.
In recognition of this treatment paradox, the American Diabetes
Association (ADA) and the American Geriatrics Society
published a joint statement providing guidance for clinicians.1
Previous American Geriatrics Society guidelines recommended
treatment aimed at achieving a glycated haemoglobin (HbA1c)
of less than 53 mmol/mol (<7%) for all adults, regardless of
age.2 The new guidance, however, emphasises the need to tailor
treatment in older people. This echoes statements from the
British Geriatrics Society and the European Diabetes Working
Party for Older People, which both supported this approach,3 4
recommending that hypoglycaemia, ability to self manage,
cognitive status, comorbidities, and life expectancy are taken
into account when making decisions on treatment.
The new joint guidance goes further than other guidelines by
offering explicit targets. For older people with little comorbidity
and preserved cognitive and physical function, the HbA1c target
is less than 58.5 mmol/mol, but for those with multiple chronic
illnesses and mild to moderate cognitive impairment who are
at risk of falls and hypoglycaemia, the target is less than 64
mmol/mol. In those with end stage chronic illnesses, moderate
to severe cognitive impairment, and those in long term care, the
HbA1c target is less than 69 mmol/mol. These guidelines could
be applied to older adults with diabetes in the United Kingdom,
where the prevalence of type 2 diabetes is 4.1%, with half of
these patients over the age of 65 years.5 Ten per cent of people
in the UK aged over 75 years and 14% aged over 85 years have
diabetes, and a substantial number may have undiagnosed
disease.
Guidance suggesting a “sliding scale” for treatment according
to age is open to criticism, but trial data to underpin treatment
for older people with diabetes are lacking. Landmark trials such
as the UK Prospective Diabetes Study excluded patients over
65 years, yet guidance has tended to extrapolate from evidence
provided by such studies. Recently, a series of high profile
studies was unable to show an improvement in cardiovascular
outcomes with intensive glycaemic control, and in one study
there was a suggestion that this approach may result in greater
harm in older people.6-8 These trial data align with observational
data that suggest an association between hypoglycaemia and
cognitive and physical decline, the underlying mechanism for
which is unclear. In patients with a long duration of diabetes,
cardiovascular disease, and other comorbidities, the risk of
hypoglycaemia associated with intensive glycaemic control may
outweigh any potential benefit.
For general practitioners in the UK, and clinicians in any
healthcare system where reimbursement is driven by achieving
specific HbA1c targets, the new guidance has important
implications. In the UK, Quality and Outcomes Framework
targets for HbA1c have recently been revised to reflect concerns
that tight control can lead to harm. However, treatment is still
target driven—clinicians must now aim for control along a range
(less than 58.5 mmol/mol, less than 64 mmol/mol, and less than
75 mmol/mol) depending on the clinical situation. Although
targets provide an important driver to improve glycaemic
control, evidence that this approach improves outcomes is
lacking, and in older people there is potential for harm. A system
that focuses on HbA1c targets is not compatible with
individualised care because the emphasis is on treating a number
rather than the patient. Clinicians should not be reassured that
a pragmatic “target” HbA1c precludes all risk of
hypoglycaemia—evidence suggests that patients with “poor”
glycaemic control (HbA1c >8%) also experience hypoglycaemia.
9
Recommendations on glycaemia control must take into account
the increase in the number of drugs available for treating
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diabetes. Dipeptidyl peptidase 4 inhibitors, glucagon-like peptide
1 receptor analogues, and sodium/glucose cotransporter 2
inhibitors have been shown to reduce HbA1c and have been
marketed as having a lower risk of hypoglycaemia, except in
combination with sulfonylureas.10-12 These drugs may seem to
be an attractive option for older people whose glycaemic control
is suboptimal but who are at risk of hypoglycaemia. However,
they are expensive and evidence that they improve patient
outcomes on hard endpoints in any age group is lacking; for
some of these drugs the glucose lowering effect is minimal.
Although these concerns apply to all patients, iatrogenic risk
will be greatest in older patients in whom comorbidity and
polypharmacy are prevalent.Whether using established or newer
drugs to treat diabetes in older people, the mantra must
remain—treat the patient not the HbA1c level.
The evidence for strict glycaemic control in older people is
incomplete, and the potential for harm is substantial. The new
guidance on revising HbA1c targets in frail older adults is
welcome only if taken in the context of individualised care. It
should be used to stimulate discussion around removing Quality
and Outcomes Framework targets for HbA1c in older people
because they form a heterogeneous group—from frail care home
residents to those who are fit and independent, all with variable
diabetes histories and associated comorbidities. A pragmatic
approach—that aims to individualise treatment while balancing
symptomatic and potential prognostic benefit against the
potential for side effects—is needed in these patients.
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